DMR

Damora Therapeutics, formerly known as Galecto, is a clinical-stage biotechnology company focused on developing disease-modifying therapies for fibrosis, inflammation, and cancer. The company's lead asset, DMR-001, is a monoclonal antibody targeting mutant calreticulin (mutCALR), a key driver in myeloproliferative neoplasms such as myelofibrosis and essential thrombocythemia. Damora is advancing a pipeline of anti-mutCALR programs and galectin inhibitors, aiming to address significant unmet needs in hematology and fibrotic diseases. Following a strategic rebranding and reverse merger in early 2026, the company is well-capitalized to progress its lead programs through clinical proof-of-concept and into Phase 3 development.